SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...
Recent advances in the study of inflammatory vasculitides have underscored the complexity of both giant cell arteritis (GCA) and Takayasu arteritis (TAK). Research has increasingly revealed the ...
Viral, bacterial, and atherosclerotic diseases are among the potential environmental causes of GCA and PMR. Possible causes include parainfluenza virus type 1, Mycoplasma pneumoniae, parvovirus B19 ...
A new point-of-care prediction tool that uses clinical and ultrasonography findings has good accuracy for identifying giant cell arteritis among patients seen in fast-track clinics. Investigators ...
(RTTNews) - AbbVie (ABBV) Tuesday said the U.S. Food and Drug Administration (FDA) has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease that ...
An observational study was conducted across three Spanish hospitals to compare two glucocorticoid regimens in treating 151 patients newly diagnosed with giant cell arteritis (mean age, 74.6 years; 71% ...
Out of 165 older patients in whom GCA was strongly suspected, 73 (44%) had the telltale "halo" sign on temporal artery ultrasound; and of those, the GCA diagnosis was unchanged when re-examined 2 ...
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the ...
Findings showed 46% of patients who received upadacitinib 15mg achieved sustained remission at week 52 compared with 29% of patients who received placebo. Patients with giant cell arteritis (GCA) who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback